BAT Launches Virtual R&D Visitor Experience

Apr.07.2022
BAT Launches Virtual R&D Visitor Experience
BAT launches virtual visitor experience showcasing cutting-edge research and development activities in various scientific fields.

January 19, 2022

 

BAT has launched a new virtual visitor experience that allows guests to "walk through" the company's research and development laboratories, meet top scientists, and view the results of new research. Tourists have the opportunity to explore the company's scientific methods and progress in reducing tobacco harm, as well as showcasing R&D activities in important and emerging fields such as biology, chemistry, toxicology, sensory science, aerosol analysis, product safety, consumer insights, and plant biotechnology. This underscores BAT's commitment to science in reducing the impact of its business on health and providing a better tomorrow. TMBAT has created a virtual R&D visitor experience, an online tour of its global R&D center located in Southampton, UK, allowing people to explore its cutting-edge science and innovation.

 

Experience is built on a foundation of the best available technology, open and transparent scientific methods, which support the reduction of risk in product portfolios and beyond nicotine activities. The company regularly welcomes visitors to its global research center, with over 3,500 people seeing the facilities firsthand since 2011. However, with travel greatly reduced, virtual experiences allow people from around the world to access and understand BAT's scientific research, reduce tobacco harm reduction (THR) activities, and gain insights and perspectives from experts.

 

David O'Reilly, PhD, the Director of scientific research at BAT, emphasized the importance of research and development as the foundation of their work. By prioritizing science and research, they have made significant progress in developing new product categories that have undergone rigorous testing and scientific validation as reduced-risk alternatives to traditional tobacco products. Their research is heavily influenced by consumer preferences and continually incorporates evolving scientific and innovative developments into their products. This approach allows them to offer a range of enjoyable, reduced-risk alternatives to cigarettes while maintaining very high safety and quality standards.

 

Our new virtual visitor experience showcases the breadth of science we are conducting and the strong scientific framework we are using to evaluate and support our products in reducing tobacco harm.

 

A virtual visitor experience has been developed, offering a one-stop center for people who wish to learn about the science behind BAT. This includes a tour through the 360-degree lab, animations, videos, scientist profiles and podcasts. The aim of this initiative is to highlight BAT's commitment in building a better future while reducing its impact on public health. BAT invests nearly £350 million annually to find innovative ways to reduce its influence on public health and aims to have 50 million non-combustible product consumers by 2030.

 

BAT conducts research in a wide range of scientific fields including molecular biology, toxicology, and chemistry, driving constant innovation and learning, and establishing the company as an industry leader.

 

Visitors who take a tour of the research and development virtual experience will be able to explore:

 

Sensory Science: This specialized department helps BAT better understand consumer product experiences and decodes them into actionable insights to support product and brand development. Biotech Laboratory: BAT scientists utilize their specialized knowledge in whole-genome sequencing, metabolomics, and computational biology to provide enhanced consumer experiences. These teams also grow plants and identify sustainable compound sources. Biology Laboratory: Scientists test BAT's new category products for potential impacts on human cells compared to cigarette smoke. Battery Laboratory: The facility revolutionizes the design, development, and testing of BAT's rechargeable devices. The batteries undergo rigorous speed tests to ensure they meet high-quality standards.

 

Original link:

 

British American Tobacco (BAT) has launched a virtual research and development visitor experience, showcasing world-class science behind their next-generation reduced-risk† nicotine products.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Product | JT Refreshes Ploom CUBE Design and Expands Japan Retail Distribution, Targeting Younger Men and Female Users
Japan Tobacco (JT) launched a refreshed Ploom CUBE design in Japan on September 8, 2026, with broader convenience-store and tobacco-retail distribution planned from October 13. The updated device retains the existing Rounded Cube form and heating platform while replacing four previous body colors with Pebble White and Cobalt Black. JT is also introducing new Front Panels and Fabric Back Covers, although the new accessories are not compatible with the previous Ploom CUBE design. The company says the update is intended to broaden appeal among younger male and female users.
Sep.09